These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 17300834)

  • 1. Cancer selective adenoviruses.
    Alemany R
    Mol Aspects Med; 2007 Feb; 28(1):42-58. PubMed ID: 17300834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of transcriptionally regulated oncolytic adenoviruses.
    Ko D; Hawkins L; Yu DC
    Oncogene; 2005 Nov; 24(52):7763-74. PubMed ID: 16299536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic adenoviruses - selective retargeting to tumor cells.
    Mathis JM; Stoff-Khalili MA; Curiel DT
    Oncogene; 2005 Nov; 24(52):7775-91. PubMed ID: 16299537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.
    Guse K; Dias JD; Bauerschmitz GJ; Hakkarainen T; Aavik E; Ranki T; Pisto T; Särkioja M; Desmond RA; Kanerva A; Hemminki A
    Gene Ther; 2007 Jun; 14(11):902-11. PubMed ID: 17377596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replication-selective oncolytic viruses in the treatment of cancer.
    Everts B; van der Poel HG
    Cancer Gene Ther; 2005 Feb; 12(2):141-61. PubMed ID: 15472714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.
    Ganesh S; Gonzalez-Edick M; Gibbons D; Van Roey M; Jooss K
    Clin Cancer Res; 2008 Jun; 14(12):3933-41. PubMed ID: 18559615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential impact of hypoxia on the success of oncolytic virotherapy.
    Hay JG
    Curr Opin Mol Ther; 2005 Aug; 7(4):353-8. PubMed ID: 16121701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virus combinations and chemotherapy for the treatment of human cancers.
    Kumar S; Gao L; Yeagy B; Reid T
    Curr Opin Mol Ther; 2008 Aug; 10(4):371-9. PubMed ID: 18683102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulated hsp70B' promoter: stringent heat-inducible activity in replication-deficient, but not replication-competent adenoviruses.
    Rohmer S; Mainka A; Knippertz I; Hesse A; Nettelbeck DM
    J Gene Med; 2008 Apr; 10(4):340-54. PubMed ID: 18265421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice.
    Ganesh S; Gonzalez Edick M; Idamakanti N; Abramova M; Vanroey M; Robinson M; Yun CO; Jooss K
    Cancer Res; 2007 May; 67(9):4399-407. PubMed ID: 17483354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms.
    Delgado-Enciso I; Cervantes-García D; Martínez-Dávila IA; Ortiz-López R; Alemany-Bonastre R; Silva-Platas CI; Lugo-Trampe A; Barrera-Saldaña HA; Galván-Salazar HR; Coronel-Tene CG; Sánchez-Santillán CF; Rojas-Martínez A
    J Gene Med; 2007 Oct; 9(10):852-61. PubMed ID: 17729237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic adenoviruses for cancer gene therapy.
    Liu TC; Thorne SH; Kirn DH
    Methods Mol Biol; 2008; 433():243-58. PubMed ID: 18679628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic viruses for the treatment of cancer: current strategies and clinical trials.
    Ries SJ; Brandts CH
    Drug Discov Today; 2004 Sep; 9(17):759-68. PubMed ID: 15450242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR).
    Singleton DC; Li D; Bai SY; Syddall SP; Smaill JB; Shen Y; Denny WA; Wilson WR; Patterson AV
    Cancer Gene Ther; 2007 Dec; 14(12):953-67. PubMed ID: 17975564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of cancer with a novel dual-targeted conditionally replicative adenovirus armed with mda-7/IL-24 gene.
    Luo J; Xia Q; Zhang R; Lv C; Zhang W; Wang Y; Cui Q; Liu L; Cai R; Qian C
    Clin Cancer Res; 2008 Apr; 14(8):2450-7. PubMed ID: 18413837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.
    Sinkovics JG; Horvath JC
    Arch Immunol Ther Exp (Warsz); 2008 Dec; 56 Suppl 1():3s-59s. PubMed ID: 19104757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?
    Kirn D
    Gene Ther; 2001 Jan; 8(2):89-98. PubMed ID: 11313778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the E3 and L3 regions for arming oncolytic adenoviruses to achieve a high level of tumor-specific transgene expression.
    Robinson M; Ge Y; Ko D; Yendluri S; Laflamme G; Hawkins L; Jooss K
    Cancer Gene Ther; 2008 Jan; 15(1):9-17. PubMed ID: 17853920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell entry targeting restricts biodistribution of replication-competent retroviruses to tumour tissue.
    Duerner LJ; Schwantes A; Schneider IC; Cichutek K; Buchholz CJ
    Gene Ther; 2008 Nov; 15(22):1500-10. PubMed ID: 18509380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.